Conversion of intravenous to oral/nasogastric antibiotics in critically ill patients with pneumonia

Canadian Journal of Hospital Pharmacy

Volumn 51, Issue 5, 1998, Pages 209-214

  Lauzon, Léna ^a   Perreault, Marc M ^a   Tierney, Michael ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antibiotics; Intensive care unit; Pneumonia; Switch therapy

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFALEXIN; CEFOTAXIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; ERYTHROMYCIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; CLINICAL ARTICLE; CRITICAL ILLNESS; FEMALE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NASOGASTRIC TUBE; ORAL DRUG ADMINISTRATION; PNEUMONIA; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME;

EID: 0031770089     PISSN: 00084123     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Mandell LA, Bergeron MG, Gribble MJ, Jewesson PJ, Low DE, Marrie TJ, et al. Sequential antibiotic therapy: effective cost management and patient care. Can J Infect Dis 1995;6:306-15.
2. Quintiliani R, Crowe HM, Nightingale C. Transitional antibiotic therapy. Can J Infect Dis 1995; 6 (suppl A): A6-A10.
3. Jewesson P. Cost-effectiveness and value of an iv switch. PharmacoEconomics 1994; 5 (suppl 2): S20-S26.
4. Craig WA, Andes DR. Parenteral versus oral antibiotic therapy. Med Clin North Am 1995; 79: 497-508.
5. Jewesson PJ. Pharmaceutical pharmacokinetics and other considerations for intravenous to oral stepdown therapy. Can J Infect Dis 1995; 6 (suppl A): A11-A16.
6. Garrard CS, A'Court CD. The diagnosis of pneumonia in the critically ill. Chest 1995; 108 (suppl): S17-S25
7. The ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-55.
8. Mandell LA, Niederman MS, The Canadian Community Acquired Pneumonia Consensus Conference Group. Antimicrobial treatment of community acquired pneumonia in adults: a conference report. Can J Infect Dis 1993; 4: 25-28.
9. Mandell LA, Marrie TJ, Niederman MS, The Canadian Hospital Acquired Pneumonia Consensus Conference Group. Initial antimicrobial treatment of hospital acquired pneumonia in adults: a conference report. Can J Infect Dis 1993; 4: 317-21.
10. Mandell LA. Community-acquired pneumonia. Etiology epidemiology, and treatment. Chest 1995; 108 (suppl): S35-S42.
11. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333: 1618-24.
12. American Thoracic Society Board of Directors. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418-26.
13. Campbell GD. Overview of community-acquired pneumonia. Prognosis and clinical features. Med Clin North Am 1994; 78: 1035-48.
14. Frighetto L, Martinusen SH, Mamdani F, Jewesson PJ. Ciprofloxacin use under a reserved drug and stepdown promotion program. Can J Hosp Pharm 1995; 48: 35-42.
15. Ramirez JA. Switch therapy in adult patients with pneumonia. Clin Pulm Med 1995; 2: 327-33.
16. Ramirez JA, Srinath L, Ankee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273-76.
17. Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic stepdown therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother 1995; 29: 561-5.
18. Chan R, Hemeryck L, O'Regan M, Clancy L, Feely J. Oral versus intravenous antibiotics for community-acquired lower respiratory tract infection in a general hospital: open, randomized controlled trial. BMJ 1995; 310: 1360-2.
19. Committee on Antimicrobial Agents, Canadian Infectious Disease Society. Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Can Med Assoc J 1994; 150: 669-76.
20. Janknegt R, van der Meer JWM. Sequential therapy with intravenous and oral cephalosporins. J Antimicrob Chemother 1994; 33: 169-77.
21. Malfair SC, Frighetto L, Nickoloff DM, Martinusen SM, Jewesson PJ. Evaluation of the use of cefuroxime and cefuroxime axetil in an intravenous-oral stepdown program. Ann Pharmacother 1996;30: 337-42.